The Four Phases of Clinical Trials | Diversity in Clinical Trials | AKF

FDA’s Clinical Regulatory Perspective: Designing First-In-Human Trial for Cellular and Gene Therapy

FDA Webinar on the Infant Formula Transition Plan for Exercise of Enforcement Discretion (Part 1)

Overview of the FDA Product-Specific Guidance Program

Designing First-In-Human Trials for Small Molecules and Biologics

FDA Approval Considerations with Dr. Paul Kluetz

FDA Webinar on New Infant Formula Transition Plan (Part 2)

Industry Panel Insights on FDA's Guidance and Inclusive Clinical Trials

Navigating clinical trials in pulmonary hypertension

FDA’s guidance on clinical trials with psychedelic drugs

Nonclinical Safety Assessment for Small Molecules and Biologic Drug Development (6of14) REdI 2018

FDA Clinical Investigator Training Course (CITC) 2023, Day 1 – Part 2

FDA Clinical Trial Guidance During COVID-19

Vol 6 - A Brief Guide to Understanding: FDA's CMC Guidance for Phase 2 and 3 INDs

Clinical Hold in ALL Study, FDA Draft Guidelines, Expanded Approval in Hodgkin Lymphoma

FDA's current thinking on cGMP compliance for Phase I Investigational Drug and Biologic products

Most Common Issues with CDISC-SEND Data in FDA Toxicology Review – Sep. 12, 2019

Worried about Your Next FDA Meeting? Key Tips to Make It a Success

Impact of FDA guidelines for risk based monitoring on clinical trials

Webinar — Comparing CTA Submission (EMA/Health Canada) to IND Applications (FDA) for Phase I Trials